Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | SCN1A | P35498 | 2/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19613603 | 0.89 | SCN8A (0.37) | SCN8ASCN1ASCN5A | |
| SCHEMBL19614272 | 0.83 | SCN8A (0.50) | SCN8ASCN1ASCN5A | |
| SCHEMBL30662725 | 0.83 | SCN8A (0.50) | SCN8ASCN1ASCN5A | |
| SCHEMBL321130 | 0.82 | SCN8A (0.35) | SCN8ASCN1ASCN5AKDM4E | |
| SCHEMBL21777875 | 0.81 | SCN8A (0.33) | SCN8A | |
| SCHEMBL20238177 | 0.81 | SCN8A (0.41) | SCN8ASCN1ASCN5AKDM4E | |
| SCHEMBL21777318 | 0.79 | SCN8A (0.33) | SCN8ASCN1ASCN5A | |
| SCHEMBL19617228 | 0.79 | SCN8A (0.38) | SCN8ASCN1ASCN5AKDM4E | |
| SCHEMBL22331206 | 0.78 | AKR1C3 (0.31) | — | |
| SCHEMBL19613849 | 0.78 | SCN8A (0.36) | SCN8ASCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3807281-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2021-04-21 | — | — | EP | disclosed |
| US-10745392-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2020-08-18 | — | — | US | disclosed |
| EP-3458449-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017201468-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745392-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | SCN8A 11/4885GRM4 1012/4885SCN1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.